Show Summary Details
Page of

Endovascular Therapy for Acute Ischemic Stroke, Part II (After IV Thrombolysis): The IMS III Trial 

Endovascular Therapy for Acute Ischemic Stroke, Part II (After IV Thrombolysis): The IMS III Trial
Chapter:
Endovascular Therapy for Acute Ischemic Stroke, Part II (After IV Thrombolysis): The IMS III Trial
Author(s):

Matthew D. Kalp

and David Y. Hwang

DOI:
10.1093/med/9780199377527.003.0037
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 21 September 2019

This chapter provides a summary of a landmark study in vascular neurology. Should patients that receive intravenous thrombolysis for acute ischemic stroke also receive additional endovascular therapy? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. Even though endovascular therapy is now the standard of care, the chapter explains why this prominent study failed to show a benefit in 90-day functional outcome of IV tissue plasminogen activator plus endovascular therapy versus IV therapy alone for acute ischemic stroke. Safety endpoints, notably death and symptomatic intracerebral hemorrhage, were largely similar in both groups. The chapter briefly reviews other relevant studies and information and concludes with the main study’s implications.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.